Antibody Drug Conjugates Market Size & Share to Surpass $13.17 Billion by 2028 | Vantage Market Research WASHINGTON, DC, April 04, 2023 (GLOBE NEWSWIRE) -- The Global Antibody Drug Conjugates (ADCS) Market is valued at USD 4.24 Billion in 2021 and is projected to attain a value of USD 13.17 Billion by...

Antibody Drug Conjugates (ADCs) Market Size to Reach USD 13.17 Billion by 2028 - Powered by Approval for Biologics License Applications – Vantage Market Research WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics...

Option Care Health Selected as Preferred Pharmacy Partner To Prepare and Distribute Breakthrough Cancer Therapy BANNOCKBURN, Ill., May 21, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate...

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer - Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...

Kura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), today announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug...